Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L E Flaherty

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Cancer|June 1, 1993
A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanomaL E Flaherty, W Robinson, B G Redman, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 10, 1998
Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group studyR P Whitehead, J M Unger, J W Goodwin, et al.
Cancer|June 1, 1990
A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanomaL E Flaherty, B G Redman, G G Chabot, et al.
Investigational New Drugs|September 20, 2001
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group studyR P Whitehead, J M Unger, L E Flaherty, et al.
Journal of the National Cancer Institute|June 3, 1992
Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trialL E Flaherty, P Y Liu, W S Fletcher, et al.
American Journal of Clinical Oncology|April 1, 1996
The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921)L E Flaherty, P Y Liu, M S Mitchell, et al.
The Cancer Journal From Scientific American|April 3, 1999
A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group studyV K Sondak, P Y Liu, L E Flaherty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190J M Kirkwood, J G Ibrahim, V K Sondak, et al.
Cancer|January 1, 1995
A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanomaM K Wallack, M Sivanandham, C M Balch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group studyK A Margolin, P Y Liu, L E Flaherty, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Cancer|June 1, 1993
A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanomaL E Flaherty, W Robinson, B G Redman, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|November 10, 1998
Phase II trial of recombinant human interleukin-4 in patients with disseminated malignant melanoma: a Southwest Oncology Group studyR P Whitehead, J M Unger, J W Goodwin, et al.
Cancer|June 1, 1990
A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanomaL E Flaherty, B G Redman, G G Chabot, et al.
Investigational New Drugs|September 20, 2001
Phase II trial of CI-980 in patients with disseminated malignant melanoma and no prior chemotherapy. A Southwest Oncology Group studyR P Whitehead, J M Unger, L E Flaherty, et al.
Journal of the National Cancer Institute|June 3, 1992
Dacarbazine and outpatient interleukin-2 in treatment of metastatic malignant melanoma: phase II Southwest Oncology Group trialL E Flaherty, P Y Liu, W S Fletcher, et al.
American Journal of Clinical Oncology|April 1, 1996
The addition of tamoxifen to dacarbazine and cisplatin in metastatic malignant melanoma. A phase II trial of the Southwest Oncology Group, (SWOG-8921)L E Flaherty, P Y Liu, M S Mitchell, et al.
The Cancer Journal From Scientific American|April 3, 1999
A phase II evaluation of all-trans-retinoic acid plus interferon alfa-2a in stage IV melanoma: a Southwest Oncology Group studyV K Sondak, P Y Liu, L E Flaherty, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2000
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190J M Kirkwood, J G Ibrahim, V K Sondak, et al.
Cancer|January 1, 1995
A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanomaM K Wallack, M Sivanandham, C M Balch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 1998
Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group studyK A Margolin, P Y Liu, L E Flaherty, et al.
Pageof 4